

This article was downloaded by:[Ohio State University Libraries]
On: 9 December 2007
Access Details: [subscription number 769141811]
Publisher: Informa Healthcare
Informa Ltd Registered in England and Wales Registered Number: 1072954
Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



International Journal of Toxicology

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713926068>

Phospholipase A₂ Activation Regulates Cytotoxicity of Methylmercury in Vascular Endothelial Cells

Jessica N. Mazerik^{ab}; Thomas Hagele^{ab}; Shariq Sherwani^{ab}; Valorie Ciapala^{ab}; Susan Butler^{ab}; M. Lakshmi Kuppusamy^{ab}; Melissa Hunter^{ab}; Periannan Kuppusamy^{ab}; Clay B. Marsh^{ab}; Narasimham L. Parinandi^a

^a Lipid Signaling and Lipidomics Laboratory, Division of Pulmonary, Allergy, Critical Care, The Ohio State University College of Medicine, Columbus, Ohio, USA

^b Sleep Medicine, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA

Online Publication Date: 01 November 2007

To cite this Article: Mazerik, Jessica N., Hagele, Thomas, Sherwani, Shariq, Ciapala, Valorie, Butler, Susan, Kuppusamy, M. Lakshmi, Hunter, Melissa,

Kuppusamy, Periannan, Marsh, Clay B. and Parinandi, Narasimham L. (2007) 'Phospholipase A₂ Activation Regulates Cytotoxicity of Methylmercury in Vascular Endothelial Cells', *International Journal of Toxicology*, 26:6, 553 - 569

To link to this article: DOI: 10.1080/10915810701707759

URL: <http://dx.doi.org/10.1080/10915810701707759>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article maybe used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Phospholipase A₂ Activation Regulates Cytotoxicity of Methylmercury in Vascular Endothelial Cells

Jessica N. Mazerik, Thomas Hagele, Shariq Sherwani, Valorie Ciapala, Susan Butler, M. Lakshmi Kuppusamy, Melissa Hunter, Periannan Kuppusamy, Clay B. Marsh, and Narasimham L. Parinandi

Lipid Signaling and Lipidomics Laboratory, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA

Mercury has been identified as a risk factor for cardiovascular disease among humans. Through diet, mainly fish consumption, humans are exposed to methylmercury, the biomethylated organic form of environmental mercury. As the endothelium is an important player in homeostasis of the cardiovascular system, here, the authors tested their hypothesis that methylmercury activates the lipid signaling enzyme phospholipase A₂ (PLA₂) in vascular endothelial cells (ECs), causing upstream regulation of cytotoxicity. To test this hypothesis, the authors used bovine pulmonary artery ECs (BPAECs) cultured in monolayers, following labeling of their membrane phospholipids with [³H]arachidonic acid (AA). The cells were exposed to methylmercury chloride (MMC) and then the release of free AA (index of PLA₂ activity) and lactate dehydrogenase (LDH; index of cytotoxicity) were determined by liquid scintillation counting and spectrophotometry, respectively. MMC significantly activated PLA₂ in a dose-dependent (5 to 15 μM) and time-dependent (0 to 60 min) fashion. Sulfhydryl (thiol-protective) agents, calcium chelators, antioxidants, and PLA₂-specific inhibitors attenuated the MMC-induced PLA₂ activation, suggesting the role of thiols, reactive oxygen species (ROS), and calcium in the activation of PLA₂ in BPAECs. MMC also induced the loss of thiols and increase of lipid peroxidation in BPAECs. MMC induced cytotoxicity in BPAECs as observed by the altered cell morphology and LDH leak, which was significantly attenuated by PLA₂ inhibitors. This study established that PLA₂ activation through thiols, calcium, and oxidative stress was associated with the cytotoxicity of MMC in BPAECs, drawing attention to the involvement of PLA₂ signaling in the methylmercury-induced vascular endothelial dysfunctions.

Keywords Arachidonic Acid, Environmental Cardiovascular Risk, Lipid Signaling, Methylmercury, Phospholipase A₂, Vascular Endothelial Cell

Received 30 May 2007; accepted 14 September 2007.

This work was supported by the National Institutes of Health grant HL 067176-05, EB 004031, and Dorothy M. Davis Heart and Lung Research Institute funds.

Address correspondence to Narasimham L. Parinandi, PhD, Room 611-A, Division of Pulmonary, Critical Care, and Sleep Medicine, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, 473 W. 12th Avenue, Columbus, OH 43210, USA. E-mail: narasimham.parinandi@osumc.edu

For years, mercury (Hg), a heavy metal belonging to the transition element series of the periodic table, has been under intense investigation as a serious environmental pollutant. It is released into the environment from the coal-burning and mining industries, power plants, and other industrial processes (Clarkson, Magos, and Myers 2003; Pleva 1994; Mutter et al. 2004). These anthropogenic activities, along with natural processes such as volcanic action, contribute to the mercury pollution of air, water, and soil (Clarkson, Magos, and Myers 2003; Sarkar et al. 2005; Kuehn 2005). A majority of the mercury to which humans are exposed is methylmercury (MMC), the bioorganic environmental form of mercury (Bellum et al. 2007). Elemental mercury is converted to methylmercury by the microorganisms (bacteria), and methylmercury is bioaccumulated in the aquatic organisms, eventually reaching humans at the top of the food chain (Boening 2000; Dopp et al. 2004).

The severe toxicity of methylmercury and the plethora of adverse biological effects the metal causes have led to its recognition as a ubiquitous environmental toxicant (Maycock and Benford 2007; Monnet-Tschudi et al. 2006). The role of mercury as a possible risk factor in the cardiovascular diseases has been emphasized (Kosta 1991; Virtanen et al. 2007) and elevated body levels of mercury, due to fish consumption by humans, have been attributed as a risk factor in the coronary heart disease (Yoshizawa et al. 2002). An association between the occupational exposure to mercury in mining and refining and risk of cardiovascular diseases has been shown (Boffetta et al. 2001). In humans, exposure to methylmercury due to fish consumption could possibly lead to suppression of the beneficial effects of omega-3 fatty acids on the coronary artery disease (Landmark and Aursnes 2004; Chan and Egeland 2004; Clarkson 2002). Although mercury exposure in humans has been shown to be associated with cardiovascular diseases, detailed studies leading to the understanding of the mechanisms of mercury-induced cardiovascular problems are currently lacking.

The vascular endothelium plays a pivotal role in the structure and function of the blood vessel and maintains the homeostasis of the circulatory system and the entire body in general. The adverse effects of mercury on the endothelium have been documented. Methylmercury has been shown to cause hypertension in rats (Wakita 1987), and mercury-induced vascular endothelial damage and vasculitis have been documented in humans upon autopsy (Egermayer 2000). Therefore, it is conceivable to hypothesize that methylmercury exerts its toxic effects on the vascular endothelium, which may contribute to the environmental mercury-induced cardiovascular diseases.

In mammalian cells, phospholipases are enzymes that specifically hydrolyze the membrane phospholipids and generate bioactive lipid second messengers, which play an important role in cell signaling (Dennis et al. 1991; Divecha and Irvine 1995). One such enzyme, phospholipase A₂ (PLA₂), is pivotal in regulating signal cascades involving the formation and repair of the phospholipid membrane and formation of inflammatory molecules (Chakraborti 2003). Aside from its job as a housekeeping enzyme (Balsinde, Winstead, and Dennis 2000), PLA₂ catalyzes the hydrolysis of the membrane phospholipid at the *sn*-2 position, generating free unsaturated fatty acid and lysophospholipid (Dennis et al. 1991; Chakraborti 2003). The unsaturated fatty acid released by PLA₂, usually arachidonic acid (AA), is a preferred substrate for the cyclooxygenases (COXs) and lipoxygenases (LOXs), which mediate the formation of bioactive AA metabolites such as the prostaglandins and leukotrienes (Chakraborti 2003). These metabolites of COX and LOX are tightly regulated by PLA₂, and have been identified as crucial players in the inflammatory cascades (Dennis et al. 1991).

PLA₂ has been shown to be activated by several agonists in different systems both in vitro and in vivo (Chakraborti 2003). Roles of PLA₂ and AA metabolites in cardiovascular diseases have been emerging (Lambert, Pedersen, and Poulsen 2006). Unregulated PLA₂ activation mediated by agonists such as environmental toxicants can jeopardize the endothelial function and eventually disrupt the blood vessel homeostasis. As environmental mercury has been implicated in the cardiovascular diseases and earlier, we have shown that mercury (inorganic and organic forms) activates phospholipase D (PLD) and PLA₂ in vascular endothelial cells (ECs) (Hagele et al. 2007; Mazerik et al. 2007). Here, we have hypothesized that methylmercury activates PLA₂ and induces the release of AA, and the activation of PLA₂ contributes to the methylmercury-induced cytotoxicity in the cultured ECs. To test our hypothesis, we investigated whether methylmercury chloride (MMC) could activate PLA₂, induce the release of AA, and regulate the MMC-induced cytotoxicity in our well-established bovine pulmonary artery ECs (BPAECs) in vitro. The current study revealed that MMC induced the release of AA by PLA₂, and PLA₂ played an important role in the regulation of the MMC-induced cytotoxicity in BPAECs.

MATERIALS AND METHODS

Materials

Bovine pulmonary artery endothelial cells (BPAECs) (passage 2) were obtained from Cell Applications Inc. (San Diego, CA). Fetal bovine serum (FBS), trypsin, minimum essential medium (MEM), and nonessential amino acids were obtained from Gibco Invitrogen (Grand Island, NY). Methylmercury chloride (MMC), *N*-acetyl-L-cysteine (NAC), meso-2,3-dimercaptosuccinic acid (DMSA), ethylene glycol-bis (β -aminoethyl ether)-*N,N,N',N'*-tetraacetic acid (EGTA), BAPTA-AM (BAPTA), pyroglutimidinedithiocarbamate (PDTTC), vitamin C, propyl gallate, 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB), and lactate dehydrogenase cytotoxicity assay (LDH) kit were obtained from Sigma Chemical Co. (St. Louis, MO). [³H]arachidonic acid (AA) was obtained from American Radiolabeled Chemicals (St. Louis, MO). Arachidonyl trifluoromethyl ketone (AACOCF₃) and bromoenol lactone (BEL) were obtained from Cayman Chemical (Ann Arbor, MI). Mn(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP) and quinacrine dihydrochloride were purchased from Calbiochem (San Diego, CA).

Cell Culture

BPAECs were cultured in MEM supplemented with 10% FBS, nonessential amino acids, antibiotics, and growth factor as described previously (Varadharaj et al. 2006; Hagele et al. 2007). Cells in culture were maintained at 37°C in a humidified environment of 5% CO₂-95% air and grown to contact-inhibited monolayers with typical cobblestone morphology. When confluence was reached, cells were trypsinized and subcultured in T 75-cm² flasks or 35-mm or 100-mm tissue culture dishes. Confluent cells showed cobblestone morphology under light microscope and stained positive for factor VIII. All experiments were conducted between 5 and 20 passages (75% to 80% confluence).

Assay of Release of Arachidonic Acid and PLA₂ Activation

Release of arachidonic acid (AA) from the cellular membrane phospholipids is widely assayed as an index of PLA₂ activity (Balsinde, Winstead, and Dennis 2000; Mazerik et al. 2007). BPAECs cultured in 35-mm dishes (5 × 10⁵ cells/dish) were labeled with carrier-free [³H]AA (5 μ Ci/ml) in complete EC media containing 10% FBS, nonessential amino acids, antibiotic, and growth factor for 12 h at 37°C in 5% CO₂-95% air. The radioactive medium was removed by aspiration and cells were incubated in serum-free MEM or MEM containing MMC at the chosen concentrations (5 to 15 μ M) for specified lengths of time (0 to 60 min). When required, cells prelabeled with [³H]AA were pretreated with the selected pharmacological agents/inhibitors for 1 h and then exposed to MMC in the absence or presence of the pharmacological inhibitors for specified lengths of time. At the end of the incubation period, the

amount/extent of AA released into the medium, as an index of PLA₂ activity, was determined by liquid scintillation counting. The extent of AA released was expressed as DPM of [³H]/dish.

Cellular Total Thiol Determination

Total cellular thiol content was measured by DTNB-coupled spectrophotometric assay according to Parinandi et al. (1999) and Hagele et al. (2007). BPAECs were grown to 100% confluence in 100-mm dishes then treated with MEM or MEM containing MMC (1 to 5 μ M) for 60 min. When required, cells were pretreated with MEM alone or MEM containing the inhibitor and then treated with MEM alone or MEM containing MMC (10 μ M). After incubation, cells were detached by gentle scraping and centrifuged at 5000 \times *g* for 10 min at 4°C. The cell pellets were then lysed using Triton X-100. Cell lysates were treated with DTNB and the absorbance was determined at 412 nm on a Spectromax plate reader. The levels of total thiols were obtained from a standard curve prepared with GSH and expressed as μ g thiols/10⁶ cells.

Morphology Assay of Cytotoxicity

Morphological changes in BPAECs grown in 35-mm dishes up to 70% confluence, following their exposure to different concentrations of MMC (0 to 25 μ M) in MEM for 1 h at 37°C in a humidified environment of 5% CO₂–95% air, were examined as an index of cytotoxicity. Images of cell morphology were digitally captured with the Nikon Eclipse TE2000-S at either 10 \times or 100 \times magnification.

LDH Assay of Cytotoxicity

BPAECs were grown up to 90% confluence in 35-mm dishes pretreated with MEM alone or MEM containing the chosen PLA₂ inhibitor (AACOCF₃ 1 μ M and BEL 1 and 5 μ M) for 1 h, then the cells were exposed to MEM containing MMC (10 μ M) for 30 min. At the end of incubation, supernatant was removed, the experiment was terminated with 1 N HCl and LDH release was measured according to the manufacturer's recommendations (Sigma Chemical, St. Louis, MO).

Lipid Peroxidation Determination

Lipid peroxidation in BPAECs, as an index of oxidative stress, following the exposure of cells to different concentrations of MMC, was determined spectrophotometrically as the formation of thiobarbituric acid-reactive substances (TBARS) according to Parinandi, Zwizinski, and Schmid (1991). The extent of MMC-induced formation of TBARS in BPAECs was expressed as absorbance at 532 nm normalized to 1 mg protein of cells at the end of treatment with MEM alone or MEM containing different concentrations of MMC.

Statistical Analysis of Data

Standard deviation (*SD*) for each data point was calculated from triplicate samples. Data were subjected to one-way analysis

of variance, and pair wise multiple comparisons was done by Dunnett's method, with *p* < .05 indicating significance.

RESULTS

Methylmercury Activates PLA₂ in a Dose- and Time-Dependent Fashion

As we have shown earlier that mercury activates PLD in ECs (Hagele et al. 2007) and inorganic mercury activates PLA₂ in ECs (Mazerik et al. 2007), here, we investigated whether MMC would induce the activation of PLA₂ and release of AA (as an index of PLA₂ activation) in BPAECs in a dose-dependent (5 to 15 μ M) fashion, following incubation of cells for 30 and 60 min with MMC. MMC significantly caused the activation of PLA₂ at 5, 10, and 15 μ M concentrations upon treatment of cells for 30 and 60 min respectively, as compared to that in the cells treated with vehicle alone (Figure 1A). The significant time-dependent activation of PLA₂ in BPAECs upon their treatment with MMC was also clearly evident. At 5 min of treatment, MMC caused a significant activation of PLA₂, which further increased at 15, 30, and 60 min of treatment with the compound as compared to the cells treated with the vehicle alone (Figure 1B). Overall, these results revealed that organic mercury (methylmercury chloride) was effective in causing a significant dose- and time-dependent activation of PLA₂ and AA release in BPAECs.

Thiol-Containing Heavy Metal Chelators Attenuate Methylmercury-Induced PLA₂ Activation

Reports have been made that the thiols (nonprotein and protein) are the targets for heavy metal cellular actions (Blanus et al. 2005; Valko, Morris, and Cronin 2005). Therefore, in order to establish the role of thiols in the MMC-induced PLA₂ activation in BPAECs, here, the effects of well-established thiol (sulfhydryl) protective agents (DMSA and PDTC) were investigated. Prior to the exposure of cells to 5 μ M MMC, cells were pretreated for 1 h with MEM alone or MEM containing the chosen thiol protective agent(s) (1 mM) and then treated with MMC in the presence of the thiol protective agent(s) for 30 min. DMSA offered effective and significant inhibition of the MMC-induced PLA₂ activation and AA release in BPAECs (Figure 2A). PDTC also caused effective and significant attenuation of PLA₂ activation in ECs induced by methylmercury (Figure 2B). Collectively, these results revealed that thiol-protective agents effectively and significantly attenuated the PLA₂ activation induced by MMC, suggesting the involvement of cellular thiols.

Antioxidants Attenuate Methylmercury-Induced PLA₂ Activation

As we have shown earlier that antioxidants attenuate the methylmercury-induced PLD activation in the vascular ECs (Hagele et al. 2007), here we investigated the effects of the well-established antioxidants on the PLA₂ activation in vascular ECs induced by MMC. Prior to exposure of cells to MMC (5 μ M),




FIGURE 1

Methylmercury activates PLA₂ in a dose- and time-dependent fashion. BPAECs (5×10^5 cells/35-mm dish) were labeled with [³H]AA (5 μCi) in complete EC medium for 12 to 18 h and then the cells were treated with MEM alone or MEM containing (A) MMC (5 to 15 μM) for 30 and 60 min and (B) MMC (5 μM) for 5 to 60 min. At the end of incubation, [³H]AA released into the medium was determined as described under Materials and Methods. Data represent mean \pm SD of three independent experiments. *Significantly different at $p < .05$ as compared to the vehicle-treated control cells.

cells were pretreated for 1 h with MEM alone or MEM containing the chosen antioxidant (vitamin C 500 μM, NAC 2 mM, propyl gallate 500 μM, and MnTBAP 1 μM) and then treated with MMC in the presence of the antioxidants for 30 min. Vitamin C, a well-established antioxidant, effectively attenuated the MMC-induced PLA₂ activation and release of AA in BPAECs

(Figure 3A). NAC, a widely-used thiol antioxidant and protective agent, also caused significant and effective attenuation of the MMC-induced PLA₂ activation in BPAECs (Figure 3B). Propyl gallate, another widely used antioxidant, also caused significant and effective attenuation of the MMC-induced PLA₂ activation and release of AA in BPAECs (Figure 3C). MnTBAP,




FIGURE 2

Thiol-containing heavy metal chelators attenuate methylmercury-induced PLA₂ activation. BPAECs (5×10^5 cells/35-mm dish) were labeled with [³H]AA (5 μCi) in complete EC medium for 12 to 18 h following which the cells were pretreated for 1 h with MEM alone or MEM containing (A) DMSA (1 mM) or (B) PDTC (1 mM) and then subjected to treatment with MEM alone or MEM containing MMC (5 μM) for 30 min. At the end of incubation, [³H]AA released into the medium was determined as described under Materials and Methods. Data represent mean \pm SD of three independent experiments. *Significantly different at $p < .05$ as compared to the cells treated with vehicle alone. **Significantly different at $P < .05$ as compared to the cells treated with MMC alone.

a superoxide dismutase mimetic, effectively attenuated the MMC-induced PLA₂ activation in the cells (Figure 3D). Overall, the results revealed that the antioxidants effectively attenuated the MMC-induced PLA₂ activation in BPAECs, and further suggested the involvement of reactive oxygen species (ROS) in the activation of the enzyme by methylmercury in ECs.

Calcium Chelators Attenuate Methylmercury-Induced PLA₂ Activation

As it has been established that mammalian cells contain a calcium-dependent form of PLA₂ (cPLA₂), here we investigated the role of calcium in the MMC-induced activation of PLA₂ by using the widely known calcium quenchers EGTA (extracellular) and BAPTA (intracellular). Prior to exposure to

MMC (5 μ M), cells were pretreated for 1 h with MEM or MEM containing the chosen calcium chelating agent (EGTA 5 mM and BAPTA 500 nM) and then treated with the mercury compound in the presence of the chelating agent(s) for 30 min. EGTA,

an extracellular calcium chelator, effectively and significantly attenuated the MMC-induced PLA₂ activation (Figure 4A). The well-known intracellular calcium chelator, BAPTA, also attenuated the MMC-induced PLA₂ activation in BPAECs (Figure 4B).




FIGURE 3

Antioxidants attenuate methylmercury-induced PLA₂ activation. BPAECs (5×10^5 cells/35-mm dish) were labeled with [³H]AA (5 μ Ci) in complete EC medium for 12 to 18 h, following which the cells were pretreated for 1 h with MEM alone or MEM containing (A) vitamin C (500 μ M), (B) NAC (2 mM), (C) propyl gallate (500 μ M), or (D) MnTBAP (1 μ M), and then subjected to treatment with MEM alone or MEM containing MMC (5 μ M) for 30 min. At the end of incubation, [³H]AA released into the medium was determined as described under Materials and Methods. Data represent mean \pm SD of three independent experiments. *Significantly different at $p < .05$ as compared to the cells treated with vehicle alone. **Significantly different at $p < .05$ as compared to the cells treated with MMC alone. (Continued)





FIGURE 3
(Continued)

These results revealed that calcium chelators effectively and significantly attenuated the MMC-induced PLA₂ activation in BPAECs, further suggesting the role of both intracellular and extracellular calcium in the enzyme activation in ECs and also the involvement of cPLA₂.

PLA₂-Specific Inhibitors Attenuate Methylmercury-Induced PLA₂ Activation

As the calcium chelators caused a significant attenuation of the MMC-induced PLA₂ activation in the BPAECs, here, we investigated the contribution of cPLA₂ in the MMC-induced

**FIGURE 4**

Calcium chelators attenuate methylmercury-induced PLA₂ activation. BPAECs (5×10^5 cells/35-mm dish) were labeled with [³H]AA (5 μCi) in complete EC medium for 12 to 18 h, following which the cells were (A) treated with MEM alone or MEM containing EGTA (5 mM), or MEM containing EGTA (5 mM) and MMC (5 μM) for 30 min. (B) BPAECs were pretreated for 1 h with MEM alone or MEM containing BAPTA (500 nM) and then exposed to MEM alone or MEM containing MMC (5 μM) for 30 min. At the end of incubation, [³H]AA released into the medium was determined as described under Materials and Methods.

Data represent mean \pm SD of three independent experiments. *Significantly different at $p < .05$ as compared to the cells treated with vehicle alone.

**Significantly different at $p < .05$ as compared to the cells treated with MMC alone.

release of AA by cells. In order to demonstrate this, we utilized the cPLA₂-specific inhibitor, AACOCF₃ (Riendeau et al. 1994), to examine its inhibitory effect on the MMC-induced release of AA by the ECs. Cells were pretreated with MEM alone or MEM containing AACOCF₃ (5 μ M) for 1 h and then treated with MMC (5 μ M) in the presence of the inhibitor for 30 min. AACOCF₃ slightly but significantly attenuated the MMC-induced AA release by BPAECs (Figure 5A). As the cPLA₂-specific inhibitor only slightly inhibited the AA release, the general PLA₂ inhibitor, quinacrine, was also tested. Quinacrine also attenuated the MMC-induced PLA₂ activation and release of AA in BPAECs (Figure 5B), thus revealing the activation of other isoforms of PLA₂ by MMC in ECs. These results confirmed that the MMC activated cPLA₂ and thus also contributed to the release of AA by the ECs, but the cPLA₂ isoform was not the only form of the enzyme contributing to the AA release in the cells under methylmercury exposure.

N-Acetylcysteine Attenuates Methylmercury-Induced Loss of Cellular Thiols

As it has been established that the cellular thiols are targets for mercury and the current study revealed that thiol protectants attenuated the MMC-induced PLA₂ activation in BPAECs, here, we examined the effect of MMC (5 μ M) on the levels of total cellular thiols in BPAECs. Cells were treated with MEM alone or MEM containing MMC (1, 3, and 5 μ M) for 1 h following which the levels of total cellular thiols were determined. As shown in Figure 6A, MMC caused a significant decrease in the total cellular thiol content as compared to the same in the vehicle-treated control cells. As thiol groups are the targets for attack by mercury and ROS (Hagele et al. 2007; Parinandi et al. 1999), the well-known thiol protectant and antioxidant, NAC (10 mM), was used to investigate the protection against the thiol loss. Cells were pretreated for 1 h with MEM alone or MEM containing NAC, and then exposed to MMC (10 μ M) for 1 h. NAC effectively and significantly caused the protection against the MMC-induced loss of the thiol groups in BPAECs. These results further suggested the role of cellular thiols in the MMC-induced PLA₂ activation in ECs, and indicated further the involvement of ROS and oxidative stress.

Methylmercury Causes Alterations in Cell Morphology

As it is known that PLA₂ is a bioactive lipid signaling enzyme that plays an important role in the EC function (Mazerik et al. 2007), we investigated the effects of MMC on the cell morphology as an index of disruption of cellular structure and cytotoxicity. Cells were treated with MEM alone or MEM containing MMC (2 to 25 μ M) and incubated for 30 min. At 30 min, phase-contrast light microscopy examination revealed that MMC caused a marked loss of cell morphology in a dose-dependent manner in BPAECs (Figure 7). These results also confirmed that MMC induced cytotoxicity in BPAECs.

Methylmercury Induces Lipid Peroxidation


Methylmercury has been shown to cause ROS generation and lipid peroxidation in cultured cells and in liver and kidney in vitro (Hagele et al. 2007; Garg and Chang 2006; Shanker and Aschner 2003; Fujimoto et al. 1988; Lin, Huang, and Huang 1996). Also, the results of earlier experiments of the current study revealed that antioxidants significantly attenuated the MMC-induced activation of PLA₂ and release of AA in BPAECs, suggesting that MMC induced the formation of ROS in ECs. Therefore, here we investigated the induction of lipid peroxidation in BPAECs upon exposure to MMC. As shown in Figure 8, MMC significantly induced lipid peroxidation in cells even at a concentration of 5 μ M (67% increase) at 1 h of treatment as compared to the same in the control untreated cells, which did not appear to change upon increasing the concentration of MMC to 10 μ M. Although MMC at a concentration of 25 μ M caused a significant increase in lipid peroxidation (40% increase) under identical conditions as compared to the same in the control untreated cells, the extent of lipid peroxidation was lower as observed in the cells exposed to MMC at 5 and 10 μ M under identical conditions for 1 h. These results revealed that MMC induced lipid peroxidation in BPAECs, further suggesting the induction of oxidative stress by methylmercury in ECs.

PLA₂ Inhibitors Protect against Methylmercury-Induced Cytotoxicity


As observed in the current study that the cPLA₂ inhibitor (AACOCF₃) and general PLA₂ inhibitor quinacrine significantly inhibited the MMC-induced activation of PLA₂ and release of AA in BPAECs, here, we investigated whether PLA₂ activation had a role in the MMC-induced cytotoxicity. Because we observed that MMC induced cytotoxicity in BPAECs in a dose-dependent manner as observed from the alterations in cell morphology, here, we used the LDH release assay of cytotoxicity to examine if the inhibitors of PLA₂ offered protection against MMC-induced cytotoxicity in BPAECs. Cells were pretreated for 1 h with MEM alone or MEM containing the chosen PLA₂ inhibitor (AACOCF₃ 1 μ M and BEL 1 and 5 μ M), then exposed to MMC (10 μ M) for 30 min. MMC caused a significant increase in the release of LDH by cells as compared to the cells treated with the vehicle alone. The cPLA₂-specific inhibitor AACOCF₃ significantly and effectively attenuated the cytotoxicity of MMC (Figure 9A). BEL, an inhibitor selective to calcium-independent PLA₂ (iPLA₂) also significantly and effectively attenuated the MMC-induced cytotoxicity (Figure 9B). Collectively, these results revealed that MMC induced cytotoxicity in BPAECs, which was attenuated by the PLA₂ inhibitors, further suggesting the role of PLA₂ in the MMC-induced cytotoxicity in ECs.

DISCUSSION

The results of the present study demonstrated that methylmercury, the environmental organic form of mercury, activated PLA₂ and induced the release of AA from the membrane phospholipids of BPAECs in a dose- and time-dependent fashion.


**FIGURE 5**

PLA₂-specific inhibitors attenuate methylmercury-induced PLA₂ activation. BPAECs (5×10^5 cells/35-mm dish) were labeled with [³H]AA (5 μCi) in complete EC medium for 12 to 18 h, following which the cells were pretreated for 1 h with MEM alone or MEM containing (A) the PLA₂-specific inhibitor quinacrine (10 μM) or (B) the cPLA₂-specific inhibitor, AACOCF₃ (5 μM) and then subjected to treatment with MEM alone or MEM containing MMC (5 μM) for 30 min. At the end of incubation, [³H]AA released into the medium was determined as described under Materials and Methods. Data represent mean \pm SD of three independent experiments. *Significantly different at $p < .05$ as compared to the cells treated with vehicle alone. **Significantly different at $p < .05$ as compared to the cells treated with MMC alone.

**FIGURE 6**

N-Acetylcysteine attenuates methylmercury-induced loss of cellular thiols. BPAECs (2×10^6 cells/100-mm dish) were treated with MEM alone or MEM containing MMC (0, 1, 3, and 5 μM) (A) for 1 h. BPAECs (2×10^6 cells/100-mm dish) were pretreated with NAC (10 mM) (B) for 1 h and then treated with MEM alone or MEM containing MMC (10 μM) for 1 h. After incubation, total cellular thiols were determined spectrophotometrically as described in Materials and Methods. Data represent mean \pm SD of three independent experiments. *Significantly different at $p < .05$ as compared to the cells treated with vehicle alone.

**Significantly different at $p < .05$ as compared to the cells treated with MMC alone.

**FIGURE 7**

Methylmercury causes alterations in cell morphology. BPAECs (5×10^5 cells/35-mm dish) were treated with MEM alone or MEM containing MMC (5 to 25 μ M) for 5 to 60 min. At the end of the incubation period, the medium was replaced with PBS containing 0.5% glucose and the cells were examined under light microscope at a magnification of 10 \times as described under Materials and Methods. Each micrograph is a representative picture obtained from three independent experiments conducted under identical conditions.

Furthermore, the study revealed that the methylmercury-induced PLA₂ activation in BPAECs was attenuated by the sulfhydryl (thiol) protectants, calcium chelators, and antioxidants indicating the involvement of cellular thiols, calcium, and ROS in the methylmercury-induced activation of PLA₂ in ECs. Induction of oxidative stress (lipid peroxidation and loss of cellular thiols) by methylmercury in BPAECs was also evident in the current study. The findings of this study also demonstrated that the cPLA₂-specific inhibitor (AACOCF₃) (Riendeau et al. 1994) and the iPLA₂-specific inhibitor (BEL) not only attenuated the methylmercury-induced activation of PLA₂ in BPAECs but also offered protection against the methylmercury-induced cytotoxicity, further establishing the upstream activation of PLA₂ and release of AA from the membrane phospholipids, as a causative mechanism of the methylmercury-induced endothelial cytotoxicity.

In the mammalian systems, PLA₂s are broadly divided into three major classes: (1) cytosolic calcium-dependent PLA₂ (cPLA₂), (2) intracellular calcium-independent PLA₂ (iPLA₂),

and (3) secretory calcium dependent PLA₂ (sPLA₂) (Lambert, Pedersen, and Poulsen 2006). PLA₂ specifically hydrolyzes the *sn*-2 fatty acid ester from the membrane phospholipids, releases the unsaturated fatty acid (typically AA), and forms the lysophospholipid (Balsinde, Winstead, and Dennis 2000). The lipid oxygenases including COXs and LOXs utilize the PLA₂-released AA as a preferred substrate and convert it into physiologically active AA metabolites (eicosanoids) such as the prostaglandins and leukotrienes (Balsinde, Winstead, and Dennis 2000). The lysophospholipid with the alkyl group at the *sn*-1 position, which is also generated from the membrane phospholipid upon the action of PLA₂, is converted into the platelet-activating factor (PAF). The eicosanoids (COX- and LOX-mediated AA metabolites) are potent bioactive lipids and act as key players in inflammation, rendering PLA₂ as a crucial lipid signaling enzyme (Dennis et al. 1991; Balsinde, Winstead, and Dennis 2000).

Although the cellular regulation of PLA₂ is complex, the regulation of cPLA₂ activity has been thoroughly investigated,




FIGURE 8

Methylmercury induces lipid peroxidation. BPAECs (2×10^6 cells/100-mm dish) were treated with MEM alone or MEM containing MMC (5 to 25 μM) for 1 h and following treatment the extent of lipid peroxidation (formation of TBARS) was determined spectrophotometrically as described in Materials and Methods.

The extent of lipid peroxidation was expressed as the absorbance at 532 nm/ 2×10^6 cells. Data represent mean \pm SD of three independent experiments.

*Significantly different at $p < .05$ as compared to the cells treated with vehicle alone.

which involves the modulation through the phosphorylation of serine residue of the enzyme catalyzed by different cell signaling kinases, including the mitogen-activated protein kinases, protein kinase A and protein kinase C (Chakraborti 2003). Nonetheless, the regulation of activities of iPLA₂ and sPLA₂ is yet to be understood in detail. ROS and lipid peroxidation have been identified to activate sPLA₂ and iPLA₂, leading to the release of AA in the macrophages (Nigam and Schewe 2000; Martinez and Moreno 2001). Oxidants such as hydrogen peroxide have been shown to induce the release of AA from membrane phospholipids of astrocytes through the activation of cPLA₂ and iPLA₂ (Xu et al. 2003). Overall, these studies have documented that PLA₂ activity is regulated by the cellular signaling cascades, ROS, and oxidative stress.

Methylmercury has been extensively studied with respect to its potency to activate PLA₂ in neurons and astrocytes (Verity et al. 1994; Aschner 2000; Shanker, Syversen, and Aschner 2003; Shanker et al. 2002). Alterations in calcium regulation and elevation of intracellular calcium levels in cerebellar neurons and NG108-15 cells upon methylmercury treatment have been observed (Limke, Bearss, and Atchison 2004; Sarafian 1993; Marty and Atchison 1998; Hare, McGinnis, and Atchison 1993). The increase in the levels of intracellular calcium and activation of phosphatidylcholine-specific phospholipase C and cPLA₂ in MDCK cells, following their exposure to methylmer-

cury, have been documented (Kang et al. 2006). Recently, we have shown that inorganic mercury as mercury chloride induces the release of AA, which is attenuated by calcium chelators in ECs and cPLA₂-specific inhibitor, suggesting the inorganic mercury-induced activation of cPLA₂ in the ECs (Mazerek et al. 2007). So far, there are no reports made on the methylmercury-induced activation of PLA₂ in the vascular ECs. For the first time, the results of the present study established that methylmercury, the predominant toxic form of environmental organic mercury, induced activation of PLA₂ and release of AA in vascular ECs, a process that was calcium dependent and ROS and oxidative stress-regulated. Furthermore, the present study also demonstrated that methylmercury induced activation of both the calcium-dependent species of PLA₂ (cPLA₂) and calcium-independent species of PLA₂ (iPLA₂) in ECs because the release of AA from the cells was attenuated by the cPLA₂-specific inhibitor (AACOCF₃) and iPLA₂-specific inhibitor (BEL). The mechanism of activation of both cPLA₂ and iPLA₂ by methylmercury in the vascular ECs, either in an independent manner or in a concerted fashion, needs further investigation.

Methylmercury-induced neurotoxicity in astrocytes and neurons has been shown to operate through the generation of ROS, induction of oxidative stress, and loss of cellular thiols including glutathione (GSH) (Shanker and Aschner 2001; Shanker





FIGURE 9

PLA₂-specific inhibitors protect against methylmercury-induced cytotoxicity. BPAECs (5×10^5 cells/35-mm dish) were pretreated with MEM alone or MEM containing (A) AACOCF₃ (1 μ M) or (B) BEL (1 and 5 μ M) for 60 min, following which the cells were treated with MEM alone or MEM containing MMC (10 μ M) for 60 min. At the end of incubation, release of LDH into the medium (as an index of cytotoxicity) was determined spectrophotometrically as described under Materials and Methods. The extent of cytotoxicity was expressed as absorbance at 562 nm/35-mm dish. Data represent mean \pm SD of three independent experiments. *Significantly different at $P < .05$ as compared to the cells treated with vehicle alone. **Significantly different at $P < .05$ as compared to the cells treated with MMC alone.

et al. 2005). Earlier, we have demonstrated that both inorganic (mercury chloride) and organic (methylmercury and thimerosal) forms of mercury cause the activation of another important lipid signaling enzyme, PLD, through the loss of cellular thiols in BPAECs (Hagele et al. 2007). Our recent study has also demonstrated the complete attenuation of the inorganic mercury-induced PLA₂ activation and AA release from BPAECs by the thiol protectants (dithiothreitol [DTT] and NAC) as well as the restoration of cellular thiols (Mazerik et al. 2007), thus suggesting the role of cellular thiols in the inorganic mercury-induced release of AA and activation of PLA₂ in ECs. Along these lines, the results of the present study also revealed that methylmercury, similar to the action of inorganic mercury (mercury chloride) as reported earlier by us, induced the loss of cellular thiols and associated activation of PLA₂ in BPAECs, which were attenuated by the thiol protectant (NAC). Trace heavy metals including mercury have been shown to react with the cellular thiols (Hagele et al. 2007). As observed in the present study, the interaction of methylmercury with cellular thiols and induction of oxidative stress (lipid peroxidation), leading to the activation of PLA₂ and

release of AA, further revealed a possible involvement of the thiol redox-dependant signaling cascade(s) or the direct interaction of organic mercury with the enzyme or both mechanisms.

The role of AA metabolites including the COX-generated prostanoids (prostaglandins, thromboxane, and prostacyclin) has been highlighted in vascular endothelial dysfunction and atherosclerosis (Reiss and Edelman 2006; Bogatcheva et al. 2005). The elevation of intracellular calcium, activation of cPLA₂, and release of AA are critical players in the COX-catalyzed formation of AA metabolites in the vascular ECs (Antonioti et al. 2003). Earlier, we have shown that inorganic mercury (mercury chloride) induces the formation of COX-generated AA metabolites in BPAECs, suggesting the activation of COXs and the formation of the AA-derived inflammatory mediators in ECs upon treatment with inorganic mercury. Moreover, the present study also demonstrated that methylmercury caused lipid peroxidation in BPAECs, which could also lead to the formation of eicosanoid-like inflammatory lipid peroxidation products (TBARS) with potent cell signaling actions in ECs, leading towards activation of PLA₂.



Mechanism of methylmercury-induced activation of PLA₂, release of AA from membrane phospholipids, formation of arachidonic acid metabolites through ROS generation, loss of thiols, and induction of oxidative stress (lipid peroxidation) and their probable roles in endothelial cytotoxicity.

Our earlier study has demonstrated that the inorganic mercury-induced cytotoxicity in BPAECs was protected by the cPLA₂-specific inhibitor (AACOCF₃), thus identifying a role for cPLA₂ in the inorganic mercury-induced EC toxicity (Mazerik et al. 2007). In the present study, we also showed that both the cPLA₂-specific inhibitor (AACOCF₃) and iPLA₂-specific inhibitor (BEL), offered protection against the methylmercury-induced cytotoxicity in BPAECs, indicating the upstream involvement of the activation of PLA₂ and release of AA in the methylmercury-induced EC toxicity. Reports have been made on the cytotoxicity of methylmercury in neurons and astrocytes (Verity et al. 1994; Aschner 2000; Shanker et al. 2002, 2003). The widely used PLA₂ inhibitor, mepacrine, has been observed to protect against the methylmercury-induced cytotoxicity in the cerebellar granule cells, associating the methylmercury-induced PLA₂ activation and cytotoxicity in those neurons (Verity et al. 1994). Furthermore, these documented findings support the results of our current study that the activation of PLA₂ (both cPLA₂ and iPLA₂) played a crucial role in the methylmercury-induced cytotoxicity in BPAECs.

PLA₂ and COXs are gaining prominence in vascular diseases and tissue ischemic damage (Hurt-Camejo et al. 2001; Phillis and O'Regan 2003). Moreover, mercury has been implicated as a risk factor in the cardiovascular diseases including myocardial infarction and coronary disease in humans (Yoshizawa et al. 2002; Kim et al. 2005; Nash 2005). Hence, the results of the current study showing that the organic form of environmental mercury (methylmercury) induced the activation of PLA₂ and release of AA through calcium signaling, altered thiol-redox status, formation of ROS, and induction of oxidative stress in the vascular ECs accentuate the understanding of mechanisms of the environmental mercury-induced cardiovascular diseases (Schema).

REFERENCES

- Antonietti, S., P. A. Fiorio, S. Pregolato, A. Mottola, D. Lovisolo, and L. Munaron. 2003. Control of endothelial cell proliferation by calcium influx and arachidonic acid metabolism: A pharmacological approach. *J. Cell Physiol.* 197:370–378.
- Aschner, M. 2000. Astrocyte swelling, phospholipase A₂, glutathione and glutamate: Interactions in methylmercury-induced neurotoxicity. *Cell Mol. Biol. (Noisy-le-grande)*. 46:843–854.
- Balsinde, J., M. V. Winstead, and E. A. Dennis. 2000. Phospholipase A₂ regulation of arachidonic acid mobilization. *FEBS Lett.* 531:2–6.
- Bellum, S., K. A. Thuett, R. J. Taylor, and L. C. Abbott. 2007. Assessment of mercury concentrations in mouse brain using different routes of administration and different tissue preparation. *Toxicol. Mech. Methods* 17:165–173.
- Blanusa, M., V. M. Varnai, M. Piasek, and K. Kostial. 2005. Chelators as antidotes of metal toxicity: Therapeutic and experimental aspects. *Curr. Med. Chem.* 12:2771–2794.
- Boening, D. W. 2000. Ecological effects, transport, and fate of mercury: A general review. *Chemosphere* 40:1335–1351.
- Boffetta, P., G. Sallsten, M. Garcia-Gomez, V. Pompe-Kirn, D. Zaridze, M. Bulbulyan, J. D. Caballero, F. Ceccarelli, A. B. Kopal, and E. Merler. 2001. Mortality from cardiovascular disease and exposure to inorganic mercury. *Occup. Environ. Med.* 58:461–466.
- Bogatcheva, N. V., M. G. Sergeeva, S. M. Dudek, and A. D. Verin. 2005. Arachidonic acid cascade in endothelial pathobiology. *Microvasc. Res.* 69:107–127.
- Chakraborti, S. 2003. Phospholipase A₂ isoforms: A perspective. *Cell Signal.* 15: 637–665.
- Chan, H. M., and G. M. Egeland. 2004. Fish consumption, mercury exposure, and heart disease. *Nutr. Rev.* 62:68–72.
- Clarkson, T. W. 2002. The three modern faces of mercury. *Environ. Health Perspect.* 110:11–23.
- Clarkson, T. W., L. Magos, and G. J. Myers. 2003. The toxicology of mercury—current exposures and clinical manifestations. *N. Engl. J. Med.* 349:1731–1737.
- Dennis, E. A., S. G. Rhee, M. M. Billah, and Y. A. Hannun. 1991. Role of phospholipases in generating lipid second messengers in signal transduction. *FASEB J.* 5:2068–2077.
- Divecha, N., and R. F. Irvine. 1995. Phospholipid signaling. *Cell* 80:269–278.
- Dopp, E., L. M. Hartman, A. M. Florea, A. W. Rettenmeier, and A. V. Hirner. 2004. Environmental distribution, analysis, and toxicity of organometal (loid) compounds. *Crit. Rev. Toxicol.* 34:301–333.
- Egermayer, P. 2000. Epidemics of vascular toxicity and pulmonary hypertension: What can be learned? *J. Intern. Med.* 247:11–17.
- Fujimoto, Y., N. Sakamoto, H. Kitaura, E. Ikeda, and T. Fujita. 1988. Stimulatory action of ascorbic acid on methylmercury-induced lipid peroxidation in rabbit kidney cortex slices. *Res. Commun. Chem. Pathol. Pharmacol.* 60:121–124.
- Garg, T. K., and J. Y. Chang. 2006. Methylmercury causes oxidative stress and cytotoxicity in Microglia: Attenuation by 15-deoxy-delta 12,14-prostaglandin J₂. *J. Neuroimmunol.* 171:17–28.
- Hagele, T. J., J. N. Mazerik, A. Gregory, B. Kaufman, U. Magalang, M. Kuppusamy, C. B. Marsh, P. Kuppusamy, and N. L. Parinandi. 2007. Mercury activates vascular endothelial cell phospholipase D through thiols and oxidative stress. *Int. J. Toxicol.* 26:57–69.
- Hare, M. F., K. M. McGinnis, and W. D. Atchison. 1993. Methylmercury increases intracellular concentrations of Ca⁺⁺ and heavy metals in NG108–15 cells. *J. Pharmacol. Exp. Ther.* 266:1626–1635.
- Hurt-Camejo, E., G. Camejo, H. Peilot, K. Oorni, and P. Kovanen. 2001. Phospholipase A₂ in vascular disease. *Circ. Res.* 89:298–304.
- Kang, M. S., J. Y. Jeong, J. H. Seo, H. J. Jeon, K. M. Jung, M. R. Chin, C. K. Moon, J. V. Bonventre, S. Y. Jung, and D. K. Kim. 2006. Methylmercury-induced toxicity is mediated by enhanced intracellular calcium through activation of phosphatidylcholine-specific phospholipase C. *Toxicol. Appl. Pharmacol.* 216:206–215.
- Kim, D. S., E. H. Lee, S. D. Yu, J. H. Cha, and S. C. Ahn. 2005. Heavy metal as risk factor of cardiovascular disease—An analysis of blood lead and urinary mercury. *J. Prev. Med. Pub. Health* 38:401–407.
- Kostka, B. 1991. Toxicity of mercury compounds as a possible risk for cardiovascular diseases. *Br. J. Ind. Med.* 48:845.
- Kuehn, B. 2005. Medical groups sue EPA over mercury rule. *JAMA.* 294:415–416.
- Lambert, I. H., S. F. Pedersen, and K. A. Poulsen. 2006. Activation of PLA₂ isoforms by cell swelling and ischemia/hypoxia. *Acta Physiol.* 187:75–85.
- Landmark, K., and I. Aursnes. 2004. Mercury, fish, fish oil and the risk of cardiovascular disease. *Tidsskr. Nor. Laegeforen.* 124:198–200.
- Limke, T. L., J. J. Bearss, and W. D. Atchison. 2004. Acute exposure to methylmercury causes Ca²⁺ dysregulation and neuronal death in rat cerebellar granule cells through an M3 muscarinic receptor-linked pathway. *Toxicol. Sci.* 80:60–68.
- Lin, T. H., Y. L. Huang, and S. F. Huang. 1996. Lipid peroxidation in liver of rats administered with methylmercuric chloride. *Biol. Trace Elem. Res.* 54:33–41.
- Martinez, J., and J. Moreno. 2001. Role of Ca²⁺-independent phospholipase A₂ on arachidonic acid release induced by reactive oxygen species. *Arch. Biochem. Biophys.* 392:257–252.
- Marty, M. S., and W. D. Atchison. 1998. Elevations of intracellular Ca²⁺ as a probable contributor to decreased viability in cerebellar granule cells following acute exposure to methylmercury. *Toxicol. Appl. Pharmacol.* 150:98–105.

- Maycock, B. J., and D. J. Benford. 2007. Risk assessment of dietary exposure to methylmercury in fish in the UK. *Hum. Exp. Toxicol.* 26:185–190.
- Mazerik, J. N., H. Mikkilineni, V. A. Kuppusamy, E. Steinhour, A. Peltz, C. B. Marsh, P. Kuppusamy, and N. L. Parinandi. 2007. Mercury activates phospholipase A₂ and induces formation of arachidonic acid metabolites in vascular endothelial cells. *Toxicol. Mech. Methods* In press.
- Monnet-Tschudi, F., M. G. Zurich, C. Boschat, A. Corbaz, and P. Honegger. 2006. Involvement of environmental mercury and lead in the etiology of neurodegenerative diseases. *Rev. Environ. Health* 21:105–117.
- Mutter, J., J. Naumann, C. Sadaghiani, H. Walach, and G. Drasch. 2004. Amalgam studies disregarding basic principles of mercury toxicity. *Int. J. Hyg. Environ. Health* 207:391–397.
- Nash, R. A. 2005. Metals in medicine. *Altern. Ther. Health Med.* 11:18–25.
- Nigam, S., and T. Schewe. 2000. Phospholipase A₂s and lipid peroxidation. *Biochim. Biophys. Acta* 1488:167–181.
- Parinandi, N. L., C. W. Zwizinski, and H. H. Schmid. 1991. Free radical-induced alterations of myocardial membrane proteins. *Arch. Biochem. Biophys.* 289:118–123.
- Parinandi, N. L., W. M. Scribner, S. Vepa, S. Shi, and V. Natarajan. 1999. Phospholipase D activation in endothelial cells is redox sensitive. *Antioxid. Redox Signal.* 1:193–210.
- Phillis, J. W., and M. H. O'Regan. 2003. The role of phospholipases, cyclooxygenases, and lipoxygenases in cerebral ischemic/traumatic injuries. *Crit. Rev. Neurobiol.* 15:61–90.
- Pleva, J. 1994. Dental mercury - A public health hazard. *Rev. Environ. Health* 10:1–27.
- Reiss, A. B., and S. D. Edelman. 2006. Recent insights into the role of prostanoids in atherosclerotic vascular disease. *Curr. Vasc. Pharmacol.* 4:395–408.
- Riendeau, D., J. Guay, P. K. Weech, F. Laliberte, J. Yergey, C. Li, S. Desmarais, H. Perrier, S. Liu, D. Nicoll-Griffith, and I. P. Street. 1994. Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa Phospholipase A₂, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. *J. Biol. Chem.* 269:15619–15624.
- Sarafian, T. A. 1993. Methylmercury increases intracellular Ca²⁺ and inositol phosphate levels in cultured cerebellar granule neurons. *J. Neurochem.* 61:648–657.
- Sarkar, B. A. 2005. Mercury in the environment: Effect on health and reproduction. *Rev. Environ. Health* 20:39–56.
- Shanker, G., and M. Aschner. 2001. Identification and characterization of uptake systems for cystine and cysteine ion cultured astrocytes and neurons: Evidence for methylmercury-targeted disruption of astrocyte transport. *J. Neurosci. Res.* 66:998–1002.
- Shanker, G., and M. Aschner. 2003. Methylmercury-induced reactive oxygen species formation in neonatal cerebral astrocytic cultures is attenuated by antioxidants. *Mol. Brain Res.* 110:85–91.
- Shanker, G., L. A. Mutkus, S. J. Walker, and M. Aschner. 2002. Methylmercury enhances arachidonic acid and cytosolic phospholipase A₂ expression in primary cultures of neonatal astrocytes. *Mol. Brain Res.* 106:1–11.
- Shanker, G., T. Syversen, J. L. Aschner, and M. Aschner. 2005. Modulatory effect of glutathione status and antioxidants on methylmercury-induced free radical formation in primary cultures of cerebral astrocytes. *Mol. Brain Res.* 137:11–22.
- Shanker, G., T. Syversen, and M. Aschner. 2003. Astrocyte-mediated methylmercury neurotoxicity. *Biol. Trace Elem. Res.* 95:1–10.
- Valko, M., H. Morris, and M. T. Cronin. 2005. Metals, toxicity and oxidative stress. *Curr. Med. Chem.* 12(10):1161–1208.
- Varadharaj, S., E. Steinhour, M. G. Hunter, T. Watkins, C. P. Baran, U. Magalang, P. Kuppusamy, J. L. Zwier, C. B. Marsh, V. Natarajan, and N. L. Parinandi. 2006. Vitamin C-induced activation of phospholipase D in lung microvascular endothelial cells: Regulation by MAP kinases. *Cell. Signal.* 18:1396–1407.
- Verity, M. A., T. Sarafian, E. H. K. Pacifici, and A. Sevanian. 1994. Phospholipase A₂ stimulation by methylmercury in neuron culture. *J. Neurochem.* 62:705–714.
- Virtanen, J. K., T. H. Rissanen, S. Voutilainen, T. P. Tuomainen. 2007. Mercury as a risk factor for cardiovascular diseases. *J. Nutr. Biochem.* 18:75–85.
- Wakita, Y. 1987. Hypertension induced by methylmercury in rats. *Toxicol. Appl. Pharmacol.* 89:144–147.
- Xu, J., S. Yu, A. Y. Sun, and G. Y. Sun. 2003. Oxidant-mediated AA release from astrocytes involves cPLA₂ and iPLA₂. *Free Radic. Biol. Med.* 34:1531–1543.
- Yoshizawa, K., E. B. Rimm, J. S. Morris, V. L. Spate, C. C. Hsieh, D. Spiegelman, M. J. Stampfer, and W. C. Willett. 2002. Mercury and the risk of coronary heart disease in men. *N. Engl. J. Med.* 347:1755–1760.